Background Since licensure in 2006, rotavirus vaccines have been introduced in more than
100 countries. The efficacy of rotavirus vaccines is variable in settings with different child …

Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), were licensed for global use in
2006. A systematic review of 48 peer-reviewed articles with postlicensure data from 24 …

Rotavirus vaccines have demonstrated impact in reducing diarrheal morbidity and mortality
worldwide. As countries begin to introduce the newly prequalified vaccines, additional data …

Background: The test-negative design is an increasingly popular approach for estimating
vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test …

Background Rotavirus vaccine use in national immunisation programmes has led to
declines in hospital admissions for rotavirus gastroenteritis among children; however, the …

Rotavirus disease is a leading global cause of mortality and morbidity in children under 5
years of age. The effectiveness of the two globally used oral rotavirus vaccines quickly …

Rotavirus vaccines have been introduced into over 95 countries globally and demonstrate
substantial impact in reducing diarrheal mortality and diarrheal hospitalizations in young …

Two rotavirus vaccines have been licensed in> 100 countries worldwide since 2006. As of
October 2105, these vaccines have been implemented in the national immunization …

Importance Rotavirus vaccines have been introduced worldwide, and the clinical
association of different rotavirus vaccines with reduction in rotavirus gastroenteritis (RVGE) …

Safety, efficacy, and cost-effectiveness are paramount to vaccine development. Following
the isolation of rotavirus particles in 1969 and its evidence as an aetiology of severe …